PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back  
Update My Profile | Advertise With Us | Visit PharmExec.com | SUBSCRIBE

Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what’s trending on social media.
Top 5 Stories :
Competition: The Best Defense
A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.

Read more

 

 
Drugs and the Patient Burden: How Far, How Fast and How Much?
A new IMS study reveals how changes in the design of commercial/employer-based health insurance plans are accelerating the push to higher patient contributions to the cost of prescribed drugs. William Looney reports.
Read more

 

 
Licensing Approval in Europe: New Options for a New Era
Leela Barham talks with the EMA's top medical officer, Hans-Georg Eichler, about a potentially game-changing drug approval program.
Read more

 

 
Harnessing Digital to Construct New Business Models
Life sciences companies must go beyond digitizing individual operations, and instead harness digital to design and construct entirely new business models, writes Brags Srinivasan.
Read more

Biosimilars, Patent Issues Dominate Political Landscape
Managing the nomination of new commissioner adds to a packed agenda for FDA this month, writes Jill Wechsler.
Read more

 
Follow Us
 
Trending on Social Media :
Navigating Post-Turing: Defining Value In Today's Landscape
Following the backlash over the Turing Pharma drug price rise, the healthcare industry can not afford to ignore the signals and must carefully consider what to do next, writes Meg Alexander.
Read more

Prix Galien to Highlight Industry Positives
Casey McDonald previews pharma's Oscars, the Prix Galien USA Awards, which this fall will bring some red carpet glamor and, hopefully, cheer to the industry.
Read more

Harnessing Digital to Construct New Business Models
Life sciences companies must go beyond digitizing individual operations, and instead harness digital to design and construct entirely new business models, writes Brags Srinivasan.
Read more